Stock VRL6 VASUNDHARA RASAYANS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vasundhara Rasayans Limited

Equities

VRL6

INE406F01010

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:58 2024-06-14 EDT 		5-day change 1st Jan Change
228.1 INR +4.32% Intraday chart for Vasundhara Rasayans Limited +2.17% +15.49%
05-28 Vasundhara Rasayans Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
04-04 Vasundhara Rasayans Limited Announces Resignation of Ashish Kedia as Director CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 163.5 117.9 70.4 222.2 367.6 396.6
Enterprise Value (EV) 1 97.69 79.17 6.699 115.1 269.7 359.5
P/E ratio 2.51 x 8.12 x 2.36 x 7.57 x 16.9 x 7.09 x
Yield 1.94% 2.7% 6.77% 2.15% 0.86% 1.6%
Capitalization / Revenue 0.99 x 0.6 x 0.33 x 0.98 x 1.37 x 1.05 x
EV / Revenue 0.59 x 0.4 x 0.03 x 0.51 x 1.01 x 0.95 x
EV / EBITDA 5.23 x 6.79 x 0.23 x 3.71 x 12.1 x 6.49 x
EV / FCF -4.29 x -2.36 x 0.4 x 3.29 x -40.6 x -4.4 x
FCF Yield -23.3% -42.3% 251% 30.4% -2.46% -22.7%
Price to Book 1.19 x 0.8 x 0.4 x 1.12 x 1.71 x 1.48 x
Nbr of stocks (in thousands) 3,178 3,178 3,178 3,178 3,178 3,178
Reference price 2 51.45 37.10 22.15 69.90 115.6 124.8
Announcement Date 18-08-07 19-09-07 20-11-30 21-09-03 22-09-06 23-08-07
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 166 197.7 212.8 226.8 267.5 379.4
EBITDA 1 18.69 11.66 29.05 31.02 22.22 55.42
EBIT 1 15.53 11.21 28.79 30.51 21.07 54.11
Operating Margin 9.36% 5.67% 13.53% 13.45% 7.88% 14.26%
Earnings before Tax (EBT) 1 90.55 20.74 39.06 39.62 30.46 74.76
Net income 1 65.19 14.53 29.88 29.36 21.73 55.91
Net margin 39.28% 7.35% 14.04% 12.94% 8.12% 14.74%
EPS 2 20.51 4.570 9.400 9.237 6.836 17.59
Free Cash Flow 1 -22.79 -33.52 16.79 35.03 -6.648 -81.69
FCF margin -13.73% -16.95% 7.89% 15.45% -2.49% -21.53%
FCF Conversion (EBITDA) - - 57.81% 112.93% - -
FCF Conversion (Net income) - - 56.2% 119.32% - -
Dividend per Share 2 1.000 1.000 1.500 1.500 1.000 2.000
Announcement Date 18-08-07 19-09-07 20-11-30 21-09-03 22-09-06 23-08-07
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 65.8 38.7 63.7 107 97.8 37.2
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -22.8 -33.5 16.8 35 -6.65 -81.7
ROE (net income / shareholders' equity) 62.2% 10.2% 18.6% 15.7% 10.5% 23.1%
ROA (Net income/ Total Assets) 5.74% 3.4% 7.91% 7.66% 5.43% 11.3%
Assets 1 1,136 427.3 378 383.5 400.2 496.1
Book Value Per Share 2 43.20 46.60 54.80 62.50 67.80 84.40
Cash Flow per Share 2 2.260 0.9800 2.550 2.170 33.90 24.30
Capex - 1.41 1.27 4.25 3.54 0.81
Capex / Sales - 0.71% 0.6% 1.87% 1.32% 0.21%
Announcement Date 18-08-07 19-09-07 20-11-30 21-09-03 22-09-06 23-08-07
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
VASUNDHARA RASAYANS LIMITED Stock Vasundhara Rasayans Limited
+15.49% 8.68M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+50.70% 791B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 225B
NOVARTIS AG Stock Novartis AG
+11.95% 218B
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VRL6 Stock
  4. Financials Vasundhara Rasayans Limited